Synta's Elesclomol In Pivotal Study In Melanoma Patients Nov. 13, 2007 By Trista Morrison A month after signing a billion-dollar deal with GlaxoSmithKline plc for elesclomol (formerly STA-4783), Synta Pharmaceuticals Corp. kicked off a pivotal Phase III trial of the drug in metastatic melanoma. (BioWorld Today)Read More
RSS